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Objective: The purpose of this UK study was to evaluate
interfraction reproducibility and body image score when
using ultraviolet (UV) tattoos (not visible in ambient
lighting) for external references during breast/chest wall
radiotherapy and compare with conventional dark ink.
Methods: In this non-blinded, single-centre, parallel
group, randomized control trial, patients were allocated
to receive either conventional dark ink or UV ink tattoos
using computer-generated random blocks. Participant
assignment was not masked. Systematic (+) and random
(s) setup errors were determined using electronic portal
images. Body image questionnaires were completed at
pre-treatment, 1 month and 6 months to determine the
impact of tattoo type on body image. The primary end
point was to determine that UV tattoo random error
(ssetup) was no less accurate than with conventional dark
ink tattoos, i.e. ,2.8mm.
Results: 46 patients were randomized to receive conven-
tional dark or UV ink tattoos. 45 patients completed
treatment (UV: n523, dark: n522). ssetup for the UV
tattoo group was ,2.8mm in the u and v directions
(p50.001 and p50.009, respectively). A larger pro-
portion of patients reported improvement in body image
score in the UV tattoo group compared with the dark ink
group at 1 month [56% (13/23) vs 14% (3/22), respec-
tively] and 6 months [52% (11/21) vs 38% (8/21),
respectively].
Conclusion: UV tattoos were associated with interfrac-
tion setup reproducibility comparable with conventional
dark ink. Patients reported a more favourable change in
body image score up to 6 months following treatment.
Advances in knowledge: This study is the first to evaluate
UV tattoo external references in a randomized con-
trol trial.
INTRODUCTION
The number of breast cancer (BC) survivors is rising with
most recent estimates suggesting there are over 500,000
such females in the UK alone.1 Consequently, an acceptable
cosmetic outcome following treatment is of importance to
females in this increasing population.2
Dark ink tattoos (1–3mm diameter) are routinely used in
the majority of radiotherapy (RT) departments to re-
produce the patient planned position and ensure precise
radiation delivery.3 Furthermore, the use of external ref-
erences, immobilization and image guidance in modern RT
practice mitigates the risk of geographic miss, ensuring
compliance with International Commission on Radiation
Units 50 guidelines.4 The Royal College of Radiologists
(RCR) cite a survey by Dobbs et al5 (2003) suggesting
systematic errors (+setup) and random errors (ssetup) of 3.2
and 2.9mm, respectively, for breast RT.
Despite the clear advantages of dark ink RT tattoos, they
are associated with the following limitations:
(a) It has been reported that 15–30% of patients with BC
experience body image concerns that persist into
survivorship6 and a number of other authors have
suggested that RT tattoos may contribute to body image
dissatisfaction.2,6–8 Changes to physical appearance and
body function are associated with poorer psychosocial
outcomes including anxiety and depression.8,9 A UK
survey of RT departments suggested that patients
undergoing breast RT do not want a permanent
reminder of treatment and are most likely to decline
permanent tattoos for cosmetic reasons (Townend 2014,
national audit results, unpublished).
(b) Melanocytic lesions or hair follicles can be mistaken for
tattoos, potentially causing errors in treatment delivery.7,10
(c) Religious or cultural beliefs may prohibit or make patients
feel uncomfortable about receiving tattoos.7
(d) It has also been reported that dark ink tattoos can be difﬁcult
to localize when patients have a dark skin tone.7
Alternatives to dark ink tattoos include semi-permanent mark-
ing methods; however, these have been found to be inferior to
dark ink tattoos in terms of patient comfort, durability and
longevity.2,11 In this study, we test the use of “ultraviolet (UV)
ink” tattoos. This ink is a light-coloured tattoo pigment com-
bined with a UV responsive ﬂuorescent dye. This ink is ob-
servable under UV light when the wavelength of emission from
the ﬂuorophore is Stokes shifted into the visible region of the
electromagnetic spectrum. However, once the excitation source
is removed, the dye does not ﬂuoresce and therefore, the tattoo
becomes “invisible” in ambient lighting.
In this study, we focus on a commercially available tattoo ink
whose active component is the non-toxic ﬂuorescent compound
7-diethylamino-4-methylcoumarin (coumarin 1) dispersed in
a melamine formaldehyde toluenesulfonamide polymer matrix
(Figure 1a). It was found that the ink had an excitation maxi-
mum of approximately 390 nm (dashed in Figure 1b) and a peak
emission at approximately 435 nm (red in Figure 1b). This light
is readily observed as a blue/green ﬂuorescence (Figure 1c).
Excitation is facilitated by the use of a handheld wavelength-
matched UV torch with a peak emission of 375 nm (65 nm, full
width at half maximum). Further spectral ﬁltering was not re-
quired to directly visualize the tattoo on the skin surface.
Several preliminary investigations using chicken and pig skin
suggest that UV ink tattoos may offer superior RTmarking than
conventional dark ink tattoos.7,10 However, further investigation
with human subjects has been recommended. A dermatology
study proposed that UV ink tattoos could be used as a discrete
method to aid the correct identiﬁcation of cutaneous biopsy
sites.12 This single patient study indicated that UV ink may have
sufﬁcient longevity to provide a record of RT throughout the
patient life, although this has not been veriﬁed, and may be
dependent on a number of variables such as UV exposure.13
These studies indicate that UV ink tattoos offer a viable alter-
native to dark ink. In addition, they may ameliorate body image
dissatisfaction and improve the patient experience of breast RT.
Indeed, a patient advocate group who were consulted about the
patient experience of RT tattoos conﬁrmed that the negative
Figure 1. Principle of invisible tattoos: (a) a wide-field fluorescence micrograph of a 106 dilution of tattoo ink in Phosphate-buffered
saline (PBS) (excited with 405nm light) is demonstrating a dye molecule dispersed in the polymer; scale bar is 3mm. (b) Spectral
properties of ultraviolet (UV) tattoo ink: excitation (Exc.) (dashed red) and emission (Em.) (solid red) spectra of the UV ink and the
emission spectrum of the handheld torch are used to visualize the dye (blue). (c) Manufactured sample skin tattooed with standard
dark (left) and UV ink (right) under ambient (top) and UV light (bottom): UV is invisible under ambient light and clearly visible under
UV illumination with a handheld UV torch; scale bar is 25mm.
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experience may impact upon survivorship for some females.
This study investigated the use of UV ink in the RT treatment of
BC. The primary aim was to evaluate interfraction re-
producibility using UV ink tattoos. Secondary aims were to as-
sess body image satisfaction, radiographer satisfaction, tattoo
visibility in dark skin tone and the time burden at the treat-
ment unit.
METHODS AND MATERIALS
This study was approved by The Royal Marsden Committee for
Clinical Research and a National Health Service Research Ethics
Committee. All females had undergone breast-conserving sur-
gery or mastectomy for early-stage invasive ductal or lobular
carcinoma (pT1-3b N0-1 M0) and had been recommended
adjuvant RT to the whole breast or chest wall (with or without
nodal irradiation or tumour bed boost). Dose prescription was
40Gy (Gy) in 15 fractions (613.35Gy/5 tumour bed boost) over
3–4 weeks.
The absorption and emission characteristics of two UV tattooing
ink products were determined using a Cary Eclipse Fluorescence
Spectrophotometer© (Agilent Technologies, Santa Clara, CA)
(Figure 1). A selection of UV torches was also tested to de-
termine peak emission wavelengths using a compact charged
coupled device spectrometer (Thorlabs, CCS175). This analysis
revealed that the selected dye (Nuclear Fallout©; Millenium
colorworks, CA) is well suited to the light emitted by the UV
torch (INOVA X5©; Nite Ize Inc., Boulder, CO), and the primary
emission wavelength of the dye is in the visible region of the
electromagnetic spectrum. Consultation with a professional
tattoo artist demonstrated that round liner (Size 3) professional
tattooist needles were the most effective for manually adminis-
tering UV ink into the dermis. The UV ink was available in 1 oz
bottles and decanted into sterile receptacles for each patient
before administration with a sterile lance.
All radiographers were trained in safe and accurate operation of
UV handheld torches, adhering to the International Commis-
sion for Non-ionizing Radiation Protection 2004.14 UV torch
emission was measured to ensure exposure limit values for the
skin and eyes would not be exceeded for the patient or user
during clinical use (exposure limit values deﬁned by In-
ternational Commission for Non-ionizing Radiation Protection
2004).16 Pre-treatment radiographers were trained in the safe
and effective administration of UV ink tattoos.
All patients were positioned on a breast board (Medtec, Indiana)
and CT scan images were acquired using 3mm slice thickness/
spacing. Tattoos were marked bilaterally and medially with the
addition of an anterior supraclavicular tattoo if required. A
hypodermic needle was used to administer dark ink tattoos as
per standard departmental practice. Measurements from ana-
tomic landmarks and photographs were taken to record the
location of UV tattoos. The handheld UV torch was used during
treatment sessions to locate and mark (using a ﬁne marker pen)
the centre of UV tattoos to facilitate daily setup.
The primary end point was interfraction reproducibility mea-
sured using electronic portal images (EPIs) acquired from the
tangential treatment ﬁelds, for Fractions 1–3, and a minimum of
once weekly thereafter. Template matching was used to register
chest wall and contour as visualized on EPIs with digitally
reconstructed radiographs to quantify displacements from the
planned position. Displacements were recorded in the u–v plane
in millimetres (Figure 2).
Secondary end points included patient body image, radiogra-
pher satisfaction, time taken at CT simulation and for treatment
delivery and ease of visualization of UV tattoos in patients with
a darker skin tone. The inﬂuence of tattoo type on body image
was measured using a 10-item validated body image scale (BIS).
Patients were asked to complete questionnaires at baseline
(before the RT planning CT scan) and at 1 and 6 months post-
CT simulation. Opportunity for verbatim responses was also
provided. Radiographers were asked to complete satisfaction
questionnaires at CT simulation and once weekly during treat-
ment. Questions were related to ease of administration and
visualization of tattoos. All questions had a response on a scale
of 0–3 with space for comments. The time-on and time-off CT
or treatment couch was recorded as well as the beam-on and
beam-off times.
A Felix von Luschan chromatic scale was modiﬁed and used by
CT simulation radiographers to record patient skin tone. The
scale was simpliﬁed into three distinct groups [White European
(1), East Asian (2) and Sub-Saharan skin tone (3)].
Statistical considerations
To rule out ssetup of .2.8mm when using UV tattoos, assuming
a serror of 2mm with dark ink tattoos and a standard deviation
of 1.0mm, 21 patients were required in each group (42 patients
in total) based on a two-sample t-test with 80% power and
a one-sided 5% signiﬁcance level.
Patients were randomized using a 1 : 1 ratio by a telephone
call to the local clinical trials and statistics unit (Clinical
Trials and Statistics Unit, Institute of Cancer Research).
Figure 2. The right anterior oblique tangential field digitally
reconstructed radiograph to illustrate the u and v directions
(arrows) in the imaging plane.
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Computer-generated random blocks were used and allocation
was non-blinded.
Statistical analyses were performed using SPSS® Statistics v. 19
(IBM Corp., New York, NY; formerly SPSS Inc., Chicago, IL).
EPI displacements were quantiﬁed for anterior and posterior
oblique beams. These displacements were averaged to determine
daily errors in u and v directions for each imaged session.
The RCR (2008)15 guidelines were used to calculate individual
and population random (ssetup, serror) and systematic (+setup,
+error) errors in both directions. Descriptive statistics were
reported and formal statistical comparisons between groups
were made using t-tests. A one-sided, one-sample t-test was used
to determine whether ssetup calculated for the UV tattoo group
were ,2.8mm in both u and v directions.
The changes in BIS from baseline to 1 month and from baseline
to 6 months were computed and compared between groups
using a Mann–Whitney U-test. Changes from baseline at each
time point were also categorized as no change, improvement or
worsening of score. Participant verbatim responses were ana-
lyzed and salient themes reported.
Radiographer satisfaction scores (RSS) were calculated and
compared between conditions for CT simulation and treatment
stages using descriptive statistics and Mann–Whitney analysis.
Scores ranged from 0 (no satisfaction) to 9 (complete satisfac-
tion). Verbatim responses were analyzed and comments repre-
senting salient themes reported.
Total session times and treatment setup durations were reported
using descriptive statistics and Mann-Whitney U-test for
comparison.
Analyses were conducted on an intention to treat basis once the
last patient had reached the 6-month follow-up.
RESULTS
46 patients (23 patients in dark ink group, 23 patients in UV ink
group) were randomized from a single UK centre between April
and July 2014. The median age of participants was 57 years
(range: 30–70 years) and the majority of patients were White
European (Table 1). There were no signiﬁcant differences in
baseline characteristics between the two groups.
One patient was consented and randomized to the dark ink group
but did not commence treatment owing to a change in clinical
management. 45 patients completed RT. All patients treated
within the study have now been followed up for 2 years and there
have been no reports of tattoos becoming visible in ambient
lighting or any tattoo-related skin toxicity for either group.
Random setup error (ssetup) for patients receiving UV tattoos
measured in the u and v directions was statistically less than the
pre-speciﬁed 2.8mm (p5 0.001; p5 0.009, respectively). No
statistically signiﬁcant differences between groups were found in
s and S errors in any direction (Table 2).
100% (45/45) and 96% (43/45) of participants completed the
body image questionnaires at 1 month and 6 months, re-
spectively, post-CT simulation. 56% (13/23) of patients with UV
tattoos reported improved body image as compared with only
14% (3/22) of those with dark ink at 1 month compared with
baseline. Worsening body image score was reported by 22%
(5/23) of patients with UV tattoos compared with 50% (11/22)
of patients with dark ink at 1 month compared with baseline.
A similar distribution was seen at the 6-month stage with
Table 1. Baseline characteristics for each group
Patient characteristics
UV ink tattoos N5 23
n (%)
Dark ink tattoos N5 22
n (%)
p-value
Age (years)
Mean (SD) 58 (12.73) 56 (8.83)
0.618
range 30–79 43–71
Surgery
Breast conservation 19 (83) 20 (91)
0.413
Mastectomy 4 (17) 2 (9)
Nodal irradiation
Yes 3 (13) 1 (5)
0.317
No 20 (87) 21 (95)
Tumour bed boost
Yes 4 (17) 8 (36)
0.150
No 19 (83) 14 (64)
Chemotherapy received
Yes 6 (26) 4 (18)
0.524
No 17 (74) 18 (82)
Skin tone
White European 16 (70) 13 (59)a
0.261East Asian 5 (22) 5 (23)
Sub-Saharan 2 (9) 4 (18)
SD, standard deviation; UV, ultraviolet.
Statistical comparisons have been made using the t-test for age, x2 test for trend for skin tone and x2 tests for all other baseline characteristics.
aBaseline data were not available for the patient who did not receive radiotherapy.
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a worse score reported by 26% (6/23) and 50% (11/22) of
patients, respectively, compared with baseline.
Median BIS was consistent for the UV tattoo group with a me-
dian score of 7 at both baseline and 1 month. However, median
BIS scores showed deterioration for the dark ink group with
scores of 5.5 and 6.5 at baseline and 1 month, respectively. At
6 months, however, median scores had improved (decreased)
from the baseline by 1.0 for the UV group and 0.5 for the dark
ink group. No statistical difference in score change was found
between groups. Comments suggested that some patients had
concerns about the visibility of dark ink reference marks as
shown below:
“I feel much better without tattoos being visible. Much more
conﬁdent”
(patient comment, UV ink group).
Some participants may associate visibility of dark ink tattoos
with cosmetic concerns or negative feelings, as illustrated below:
“I don’t really have a problem with the tattoos but yes they do
serve to remind you of a particularly traumatizing experience”
(patient comment, dark ink group).
Median CT simulation time was 16min [interquartile range
(IQR): 8min; range: 9–45min] vs 20min (IQR: 8min; range:
15–35min) for the dark and UV ink groups, respectively. Me-
dian treatment setup time increased from 5min (IQR: 2min;
range: 2–16min) to 6min (IQR: 3min; range: 1–24min) for
dark ink and UV ink groups, respectively. Total treatment ses-
sion median times were increased from 9min (IQR: 5min;
range: 4–48min) to 10min (IQR: 5min; range: 4–48min) for
dark and UV ink groups, respectively (Table 3). Differences in
CT simulation, setup and total treatment times were found to be
statistically signiﬁcant.
Table 2. Setup accuracy data [in millimetres (mm)] in u and v directions (in mm)
Direction UV ink group Dark ink group Significance. (two-tailed)
v
MD 20.3 20.3 –
S 1.5 1.1 0.865
s 2.1 1.5 0.068
u
MD 20.3 20.8 –
S 2.0 1.7 0.337
s 2.0 1.8 0.469
S, population systematic error; s, population random error; MD, population mean displacement; UV, ultraviolet.
Table 3. Timing data
Radiotherapy stage Descriptive statistics Dark ink type UV ink type Mann–Whitney p-values
CT simulation
Median 16 20
0.0203
Q1 14 17
Q3 22 25
Minimum 9 15
Maximum 45 35
Treatment setup time (min)
Median 5 6
,0.0001
Q1 4 5
Q3 6 8
Minimum 2 1
Maximum 16 24
Treatment total time (min)
Median 9 10
0.0138
Q1 7 8
Q3 12 13
Minimum 4 4
Maximum 48 48
UV, ultraviolet.
Q1 5 Quartile 1.
Q2 5 Quartile 2.
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Median RSS were lower when using UV tattoos compared with
dark ink at CT simulation and Week 2 time points (8 vs 9,
respectively). Median scores were equivalent for Weeks 1 and 3
(9 vs 9, respectively), but the range in RSS was greater for UV
tattoos (Figure 3). Lower scores observed for the UV tattoo
group were found to be statistically signiﬁcant for all stages of
the treatment pathway except Week 1.
Radiographer UV tattoo comments (CT simulation n5 12;
treatment n5 28) revealed that difﬁculty in administering tat-
toos and poor visibility on some Patient’s skin were likely re-
sponsible for reduced satisfaction. Radiographers were not able
to locate all UV tattoos in both patients with Sub-Saharan skin
tone (Category 3 skin tone). These patients were retattooed with
standard dark ink; however, one comment suggested there was
further difﬁculty in locating the dark ink tattoos for one of these
participants, and the anterior UV tattoo was still used for setup.
DISCUSSION
This study has shown that setup accuracy using UV ink tattoos
is comparable with that using standard dark ink. Moreover, the use
of UV ink is associated with a more favourable change in patients’
body image score compared with conventional dark ink.
The study sample captured a broad age range of female patients
and was representative of a South-West London population. The
absence of any reported tattoo ink skin reactions was consistent
with other authors’ assertions.7,16 Furthermore, this ﬁnding
implies that there is great potential for the clinical use of UV ink
in RT treatment setups.
Setup accuracy data indicate that UV tattoos are associated with
clinically acceptable interfraction reproducibility and therefore
may be used as an alternative to dark ink tattoos. The lack of
a statistically signiﬁcant difference between setups with the two
marking methods is reassuring, although the study was not
powered to detect small differences in serror and +error between
the two groups. Overall, UV tattoo setup accuracy was within
RCR (2008) recommendations (,3mm).15
BIS comparison can only be made between the time points
captured, as many variables known to inﬂuence body image
could not be controlled for in this small sample, e.g. type of
surgery;17,18 however, baseline characteristics showed no sig-
niﬁcant differences between the groups. Some authors found
that body image is sensitive to time since surgery17 and so, BIS
cannot be solely attributable to tattoo type; however, differences
in the direction or degree of change between groups may in-
dicate an effect.
Results suggest that invisible tattoos have a less negative impact
on body image compared with dark ink. However, such a large
difference between the groups is perhaps unexpected and could
be the result of anticipation bias; i.e. as the study was non-
blinded, patients may have been inﬂuenced by their randomi-
zation, with patients with UV tattoo scoring more favourably
compared with the dark ink group.
It is difﬁcult to know whether such differences between the
groups are a result of tattoo type, bias or other variables that
could not be controlled for. However, comments suggest that
a proportion of patients value having invisible markings.
By offering UV tattoos, departments are likely to improve the
patient experience of breast RT by offering choice and
addressing the cosmetic and psychological concerns associated
with conventional dark ink tattoos.
Radiographers reported greater satisfaction using conventional
dark ink tattoos. Comments indicated that difﬁculty in admin-
istering and increased time to locate UV tattoos were partly
responsible. Comments suggested that radiographer training
and exposure to this new tattooing technique is important to
deliver consistent, viable markings. Despite lower radiographer
satisfaction, UV tattoos were visible in all participants except in
those with Sub-Saharan skin tone (91%, n5 21/23). However,
because of the small number of patients with Category 3 skin
tone recruited (n5 2), it is not possible to comment on the role
of UV tattoos to enhance visibility in patients with a darker skin
tone and further investigation is required.
Timing analysis suggested there was an increase in CT simula-
tion time. This is likely attributable to time spent measuring and
documenting UV tattoo location and taking additional photos.
Setup time and overall treatment time were also marginally in-
creased in the UV tattoo group. This could be partly accounted
for by the need to use a UV light source to highlight markings,
which constitutes an additional task within the workﬂow. Dif-
ﬁculty in visualizing tattoos in some participants may also
contribute to the protracted setup and treatment times recorded.
UV tattoos offer clinically acceptable interfraction reproducibility
compared with conventional dark ink when used to set up
patients with white European and East Asian skin tones.
A difference in change of BIS between the two groups suggests
improved satisfaction with UV tattoos. Patient comments
further support the hypothesis that a signiﬁcant proportion of
females are likely to derive beneﬁt from not having dark ink
RT markings.
Figure 3. Radiographer satisfaction scores for ultraviolet (UV)
(left) and dark (right) ink tattoos at CT simulation and each
week of treatment.
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CONCLUSION
UV tattoos offer setup accuracy comparable with that of
conventional dark ink and may improve patient experience of
breast RT. UV tattoos are also associated with an improve-
ment in BIS compared with standard dark ink.
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